1
|
Zambelli A, Gallerani E, Garrone O, Pedersini R, Rota Caremoli E, Sagrada P, Sala E, Cazzaniga ME. Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence. Crit Rev Oncol Hematol 2023; 191:104104. [PMID: 37659765 DOI: 10.1016/j.critrevonc.2023.104104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 08/10/2023] [Accepted: 08/15/2023] [Indexed: 09/04/2023] Open
Abstract
Hormone-receptor positive (HR+), Human-Epidermal-growth Factor negative (HER2-) breast cancer, including the Luminal A and the Luminal B subtypes, is the most common in women diagnosed with early-stage BC. Despite the advances in screening, surgery and therapies, recurrence still occurs. Therefore, it is important to identify early those factors that significantly impact the recurrence risk. Based on current evidence and their professional expertise, a Panel of oncologists discussed the definition of high risk of recurrence in early breast cancer. Histological grade, nodal involvement, genomic score, histological grade, tumor size, and Ki-67 proliferation index were rated as the most important factors to define the high risk in patients with early breast cancer. All these factors should be considered comprehensively to tailor the choice of treatment to the peculiar characteristics of each patient.
Collapse
Affiliation(s)
- A Zambelli
- Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - E Gallerani
- Ospedale di Circolo di Varese, Varese, Italy
| | - O Garrone
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
| | | | | | - P Sagrada
- Onco-Hematology Unit, ASST Lodi, Lodi, Italy
| | - E Sala
- Oncology Unit, ASST Monza Ospedale San Gerardo, Monza, Italy
| | - M E Cazzaniga
- School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy; Phase 1 Research Unit, Fondazione IRCCS san Gerardo dei Tintori, Monza, Italy.
| |
Collapse
|
2
|
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. J Clin Oncol 2023:JCO2202900. [PMID: 36917758 DOI: 10.1200/jco.22.02900] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
Abstract
PURPOSE Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo. Here, we present the 10-year results. METHODS We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive or unknown DCIS) to low-dose tamoxifen or placebo after surgery with or without irradiation. The primary end point was the incidence of invasive breast cancer or DCIS. RESULTS The TAM-01 population included 500 women (20% atypical ductal hyperplasia, 11% LCIS, and 69% DCIS). The mean (±SD) age at the start of treatment was 54 ± 9 years, and 58% of participants were postmenopausal. After a median follow-up of 9.7 years (IQR, 8.3-10.9 years), 66 breast cancers (15 in situ; 51 invasive) were diagnosed: 25 in the tamoxifen group and 41 in the placebo group (annual rate per 1,000 person-years, 11.3 with tamoxifen v 19.5 with placebo; hazard ratio [HR], 0.58; 95% CI, 0.35 to 0.95; log-rank P = .03). Most recurrences were invasive (77%) and ipsilateral (59%). Regarding contralateral breast cancer incidence, there were six events in the tamoxifen arm and 16 in the placebo arm (HR, 0.36; 95% CI, 0.14 to 0.92; P = .025). The number needed to be treated to prevent one case of breast event with tamoxifen therapy was 22 in 5 years and 14 in 10 years. The benefit was seen across all patient subgroups. There was a significant 50% reduction of recurrence with tamoxifen in the DCIS cohort, which represents 70% of the overall population (HR, 0.50; 95% CI, 0.28 to 0.91; P = .02). No between-group difference in the incidence of serious adverse events was reported during the prolonged follow-up period. CONCLUSION Tamoxifen 5 mg once daily for 3 years significantly prevents recurrence from noninvasive breast cancer after 7 years from treatment cessation without long-term adverse events.
Collapse
Affiliation(s)
| | - Matteo Puntoni
- Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy
| | | | | | - Luca Boni
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | | | | | | | - Livia Giordano
- Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy
| | | | - Laura Cortesi
- Azienda Ospedaliera-Universitaria Policlinico di Modena, Modena, Italy
| | - Fabio Falcini
- Dipartimento Onco-ematologico AUSL-Romagna, Ravenna, Italy.,IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l., Meldola, (FC), Italy
| | - Patrizia Serra
- IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l., Meldola, (FC), Italy
| | - Franca Avino
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
| | - Francesco Millo
- Ospedali Riuniti ASL AL-Ospedale SS. Antonio e Margherita, Tortona (AL), Italy
| | | | | | | | | | - Giuseppe Aprile
- Dipartimento di Oncologia, Ospedale San Bortolo, Azienda ULSS 8 Berica, Vicenza, Italy
| | - Maria Renne
- Azienda Ospedaliera Mater Domini, Catanzaro, Italy
| | | | - Andrea DeCensi
- IEO-European Institute of Oncology IRCCS, Milan, Italy.,Ente Ospedaliero Ospedali Galliera, Genoa, Italy.,Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| |
Collapse
|
3
|
Nigro O, Chini C, Marcon IGA, De Giorgi A, Bascialla L, Gallerani E, Giaquinto A, De Palma D, Lombardo M. Metastatic basal cell carcinoma to the bone: A case of bone metastasis in uncommon sites. Dermatol Reports 2022; 14:9267. [PMID: 36199894 PMCID: PMC9527680 DOI: 10.4081/dr.2022.9267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Accepted: 05/21/2021] [Indexed: 11/24/2022] Open
Abstract
Basal cell carcinoma (BCC) is the most common malignant tumor of the skin. Despite the indolent nature, metastatic BCC can occur, albeit rarely. Metastasis to the bone is very rare. From its approval, mBCC patients are treated with vismodegib, a selective hedgehog pathway inhibitor. Unfortunately, in recent period, it was demonstrated an emergence of drug resistance, due to Smoothened (SMO) mutation. To date, several groups are studying the effectiveness of immunotherapy in BCC. Clinical trials with Immune Checkpoint Inhibitors are ongoing. We report the rare case of a man with multiple bony metastasis, with a resistance to vismodegib, and we evaluated all manuscripts in literature reporting bone metastasis. Moreover, we review all the manuscripts in literature reporting bone metastasis, and we summarize the main therapeutic strategies, and the further perspectives.
Collapse
|
4
|
Gallerani E, Nigro O, Marrazzo C, Bascialla L, Gueli R, Grigioni E, De Giorgi A, Giaquinto A, Pinotti G. CDK INHIBITORS PLUS LETROZOLE IN FIRST-LINE TREATMENT HR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER (ABC) WOMEN WITH VISCERAL DISEASE: TIME TO TURN PAGE? Breast 2019. [DOI: 10.1016/s0960-9776(19)30694-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Forssmann U, Woelfel T, Kaempgen E. Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. Cancer Immunol Res 2015; 4:18-25. [PMID: 26563311 DOI: 10.1158/2326-6066.cir-15-0105] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Accepted: 09/04/2015] [Indexed: 11/16/2022]
Abstract
Previous cancer vaccination trials often aimed to activate CD8(+) cytotoxic T-cell (CTL) responses with short (8-10mer) peptides and targeted CD4(+) helper T cells (TH) with HLA class II-binding longer peptides (12-16 mer) that were derived from tumor antigens. Accordingly, a study of immunomonitoring focused on the detection of CTL responses to the short, and TH responses to the long, peptides. The possible induction of concurrent TH responses to short peptides was widely neglected. In a recent phase I vaccination trial, 53 patients with different solid cancers were vaccinated with EMD640744, a cocktail of five survivin-derived short (9- or 10-mer) peptides in Montanide ISA 51VG. We monitored 49 patients and found strong CD8(+) T-cell responses in 63% of the patients. In addition, we unexpectedly found CD4(+) TH cell responses against at least two of the five short peptides in 61% (23/38) of the patients analyzed. The two peptides were recognized by HLA-DP4- and HLA-DR-restricted TH1 cells. Some short peptide-reactive (sp)CD4 T cells showed high functional avidity. Here, we show that a short peptide vaccine is able to activate a specific CD4(+) T-cell repertoire in many patients, facilitating a strong combined CD4(+)/CD8(+) T-cell response.
Collapse
Affiliation(s)
- Stefanie Gross
- Department of Dermatology, University Hospital of Erlangen, Germany.
| | - Volker Lennerz
- III. Medizinische Klinik und Poliklinik, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
| | - Elisa Gallerani
- IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Nicolas Mach
- Clinical Research Unit of the Foundation Dr. Henri Dubois-Ferrière Dinu Lipatti, Oncology Center, Hôpitaux Universitaires de Genève (HUG), Genève, Switzerland
| | - Steffen Böhm
- Onkologie/Hämatologie, Kantonsspital, St. Gallen, Switzerland
| | - Dagmar Hess
- Onkologie/Hämatologie, Kantonsspital, St. Gallen, Switzerland
| | - Lotta von Boehmer
- Department of Oncology, University Hospital Zurich, Zurich, Switzerland
| | - Alexander Knuth
- Department of Oncology, University Hospital Zurich, Zurich, Switzerland
| | - Adrian Ochsenbein
- Klinik und Poliklinik für Medizinische Onkologie, Inselspital, Bern, Switzerland
| | | | - Ulf Forssmann
- Merck Serono S.A., Geneva, Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany
| | - Thomas Woelfel
- III. Medizinische Klinik und Poliklinik, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
| | - Eckhart Kaempgen
- Department of Dermatology, University Hospital of Erlangen, Germany
| |
Collapse
|
6
|
Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Br J Clin Pharmacol 2015; 80:128-38. [PMID: 25580946 DOI: 10.1111/bcp.12583] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 12/08/2014] [Accepted: 12/31/2014] [Indexed: 11/30/2022] Open
Abstract
AIMS Namitecan is a new camptothecan compound undergoing early clinical development. This study was initiated to build an integrated pharmacokinetic (PK) and pharmacodynamic (PD) population model of namitecan to guide future clinical development. METHODS Plasma concentration-time data, neutrophils and thrombocytes were pooled from two phase 1 studies in 90 patients with advanced solid tumours, receiving namitecan as a 2 h infusion on days 1 and 8 every 3 weeks (D1,8) (n = 34), once every 3 weeks (D1) (n = 29) and on 3 consecutive days (D1-3) (n = 27). A linear three compartment PK model was coupled to a semiphysiological PD-model for neutrophils and thrombocytes. Data simulations were used to interrogate various dosing regimens and give dosing recommendations. RESULTS Clearance was estimated to be 0.15 l h(-1), with a long terminal half-life of 48 h. Body surface area was not associated with clearance, supporting flat-dosing of namitecan. A significant and clinically relevant association was found between namitecan area under the concentration-time curve (AUC) and the percentage drop of neutrophils (r(2) = 0.51, P < 10(-4)) or thrombocytes (r(2) = 0.49, P < 10(-4)). With a target for haematological dose-limiting toxicity of <20%, the recommended dose was defined as 12.5 mg for the D1,8 regimen, 23 mg for the once every 3 week regimen and 7 mg for the D1-3 regimen. CONCLUSION This is the first integrated population PK-PD analysis of the new hydrophilic topoisomerase I inhibitor namitecan, that is currently undergoing early clinical development. A distinct relationship was found between drug exposure and haematological toxicity, supporting flat-dosing once every 3 weeks as the most adequate dosing regimen.
Collapse
Affiliation(s)
- M Joerger
- Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.,Clinical Research Facility, Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland
| | - D Hess
- Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland.,Clinical Research Facility, Department of Medical Oncology & Hematology, Cantonal Hospital, St Gallen, Switzerland
| | - A Delmonte
- European Institute of Oncology, Milan, Italy
| | - E Gallerani
- IOSI Oncology Insitute of Southern Switzerland, Bellinzona, Switzerland
| | - A Fasolo
- Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Scientific Institute, Milan, Italy
| | - L Gianni
- Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Scientific Institute, Milan, Italy
| | - S Cresta
- IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Barbieri
- Sigma-Tau Research Switzerland S.A., Mendrisio, Switzerland
| | - S Pace
- Sigma-Tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - C Sessa
- IOSI Oncology Insitute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
7
|
Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA, Partridge AH. Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? Breast 2015; 24:201-7. [PMID: 25662412 DOI: 10.1016/j.breast.2015.01.005] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 01/09/2015] [Accepted: 01/16/2015] [Indexed: 10/24/2022] Open
Abstract
Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy.
Collapse
Affiliation(s)
- Olivia Pagani
- Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, 3008 Bern, Switzerland.
| | - Monica Ruggeri
- International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, 3008 Bern, Switzerland
| | - Silvia Manunta
- Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland
| | - Christobel Saunders
- School of Surgery, University of Western Australia, Perth, WA 6009, Australia
| | - Fedro Peccatori
- Fertility & Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology (IEO), Via Ripamonti 435, 20141 Milan, Italy
| | - Fatima Cardoso
- Breast Unit, Champalimaud Cancer Centre, Av. De Brasília, Doca de Pedrouços, 1400 - 038 Lisbon, Portugal
| | - Bella Kaufman
- Breast Cancer Service for Young Women, Oncology Institute, Sheba Medical Center, Tel Hashomer, 52621, Israel
| | - Shani Paluch-Shimon
- Breast Cancer Service for Young Women, Oncology Institute, Sheba Medical Center, Tel Hashomer, 52621, Israel
| | - Hanan Gewefel
- Woman and Fetal Imaging Clinic (WAFI), 2 Mohamed Farid Wagdy St., Suite41 Manial Al Roda Island, Cairo, Egypt
| | - Elisa Gallerani
- Ospedale Multimedica, Viale Piemonte 70, Castellanza, VA, Italy
| | - O Malkahi Abulkhair
- Department of Oncology, King Abdul Aziz Medical City for National Guard, Riyadh, Saudi Arabia
| | - Barbara Pistilli
- Oncology Department Macerata Hospital, Via S. Lucia 1, 62100 Macerata, Italy
| | - Ellen Warner
- Sunnybrook Health Sciences Centre, Odette Cancer Centre, Medical Oncology, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
| | - Emmanouil Saloustros
- Hereditary Cancer Clinic, Dpt of Medical Oncology, University Hospital of Heraklion, Voutes, Box 1352, Heraklion 71110, Greece
| | - Lucien Perey
- Greeceo Unité d'oncologie, Ensemble hospitalier de la Côte, Hôpital de Morges, Morges and Centre pluridisciplinaire d'oncologie (CePO), CHUV, Lausanne, Switzerland
| | - Khalil Zaman
- CHUV-Centre d'Oncologie, Rue du Bugnon 46, 1011 Lausanne, Switzerland
| | - Manuela Rabaglio
- Universitätsklinik und Poliklinik für Medizinische Onkologie/Brust-und Tumor Zentrum der Frauenklinik, Inselspital, Freiburgstrasse, 3010 Bern, Switzerland
| | - Shari Gelber
- IBCSG Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Boston, MA, USA
| | - Richard D Gelber
- IBCSG Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Boston, MA, USA
| | - Aron Goldhirsch
- International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, 3008 Bern, Switzerland; Program of Breast Health, European Institute of Oncology (IEO), Via Ripamonti, 435, 20141 Milano, Italy
| | - Larissa Korde
- Division of Medical Oncology, University of Washington, Seattle, WA, USA
| | - Hatem A Azim
- Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de, Bruxelles, Brussels, Belgium
| | - Ann H Partridge
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 12, Boston, MA 02215, USA
| |
Collapse
|
8
|
Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clin Cancer Res 2014; 20:5663-71. [DOI: 10.1158/1078-0432.ccr-14-0719] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014; 63:381-94. [PMID: 24487961 PMCID: PMC11029529 DOI: 10.1007/s00262-013-1516-5] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Accepted: 12/26/2013] [Indexed: 12/22/2022]
Abstract
PURPOSE Survivin is a member of the inhibitor-of-apoptosis family. Essential for tumor cell survival and overexpressed in most cancers, survivin is a promising target for anti-cancer immunotherapy. Immunogenicity has been demonstrated in multiple cancers. Nonetheless, few clinical trials have demonstrated survivin-vaccine-induced immune responses. EXPERIMENTAL DESIGN This phase I trial was conducted to test whether vaccine EMD640744, a cocktail of five HLA class I-binding survivin peptides in Montanide(®) ISA 51 VG, promotes anti-survivin T-cell responses in patients with solid cancers. The primary objective was to compare immunologic efficacy of EMD640744 at doses of 30, 100, and 300 μg. Secondary objectives included safety, tolerability, and clinical efficacy. RESULTS In total, 49 patients who received ≥2 EMD640744 injections with available baseline- and ≥1 post-vaccination samples [immunologic-diagnostic (ID)-intention-to-treat] were analyzed by ELISpot- and peptide/MHC-multimer staining, revealing vaccine-activated peptide-specific T-cell responses in 31 patients (63 %). This cohort included the per study protocol relevant ID population for the primary objective, i.e., T-cell responses by ELISpot in 17 weeks following first vaccination, as well as subjects who discontinued the study before week 17 but showed responses to the treatment. No dose-dependent effects were observed. In the majority of patients (61 %), anti-survivin responses were detected only after vaccination, providing evidence for de novo induction. Best overall tumor response was stable disease (28 %). EMD640744 was well tolerated; local injection-site reactions constituted the most frequent adverse event. CONCLUSIONS Vaccination with EMD640744 elicited T-cell responses against survivin peptides in the majority of patients, demonstrating the immunologic efficacy of EMD640744.
Collapse
Affiliation(s)
- Volker Lennerz
- III. Medical Clinic/Hematology/Oncology, Verfügungsgebäude f. Forschung and Entwicklung, University Medical Center, Johannes Gutenberg University Mainz, Obere Zahlbacher Straße 63, 55131, Mainz, Germany,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TRJ, Plummer R, Gallerani E, Kaye SB, Olmos D. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. Ann Oncol 2014; 25:1222-8. [PMID: 24608201 DOI: 10.1093/annonc/mdu108] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Although sarcomas account for only 1% of all solid tumours, patients with sarcomas comprise a larger proportion of patients entering phase I trials, due to the limited number of registered or active drugs for these diseases. To help in patient selection, we evaluated the utility of the predictive Royal Marsden Score which had been derived in carcinoma patients. In addition, we analysed efficacy and toxicity regarding the sarcoma population enrolled in phase I trials. PATIENTS AND METHODS We used data from a European Database comprising 2182 patients treated in phase I trials in 14 European institutions between 2005 and 2007. RESULTS One hundred and seventy-eight patients diagnosed with advanced sarcoma or other mesenchymal tumours were identified and accounted for 217 phase I trial participations during the study period. Histological type, class of drug, number of metastatic sites, high serum lactate dehydrogenase activity (LDH), low albumin and high white blood cell count were independent prognostic factors. Poor performance status (PS), liver metastases and high leucocyte count were associated with increased risk of early death. The class of drug used was the strongest predictor of progression-free survival (PFS) duration, inhibitors of angiogenesis and histone deacetylase giving the best results. Poor PS, high serum LDH and low lymphocyte count correlated with shorter PFS. In this heterogeneous population, PFS with investigational agents appeared comparable with that previously published for patients receiving standard treatments beyond first line. CONCLUSION Prognostic factors in sarcoma patients do not differ from a broader phase I population. Efficacy measures suggest that some patients with sarcoma derive benefit from therapy in this setting which could therefore be considered for patients with no remaining standard therapeutic option.
Collapse
Affiliation(s)
- P A Cassier
- Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton The Institute of Cancer Research, Sutton, UK Departments of Medical Oncology
| | - V Polivka
- Biostatistics, Centre Léon Bérard, Lyon
| | - I Judson
- Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton The Institute of Cancer Research, Sutton, UK
| | - J-C Soria
- Department of Medicine, Institut Gustave Roussy, Villejuif
| | - N Penel
- Department of General Cancer, Centre Oscar Lambret, Lille, France
| | - S Marsoni
- Southern Europe New Drug Organization Foundation, Milan, Italy
| | - J Verweij
- Erasmus University Medical Center, Cancer Institute, Rotterdam
| | - J H Schellens
- The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - R Morales-Barrera
- Research Unit for Molecular Therapy of Cancer, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - P Schöffski
- Department of General Medical Oncology, University Hospitals Leuven, Leuven Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium
| | - E E Voest
- University Medical Center Utrecht, Utrecht, The Netherlands
| | - C Gomez-Roca
- Department of Medicine, Institut Gustave Roussy, Villejuif
| | - T R J Evans
- The Beatson West of UK Cancer Centre, Glasgow
| | - R Plummer
- Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK
| | - E Gallerani
- Department of Oncology, Istituto Oncologico Della Svizzera Italiana, Bellinzona, Switzerland
| | - S B Kaye
- Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton The Institute of Cancer Research, Sutton, UK
| | - D Olmos
- Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton The Institute of Cancer Research, Sutton, UK
| |
Collapse
|
11
|
Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Invest New Drugs 2013; 31:1236-43. [DOI: 10.1007/s10637-013-9942-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Accepted: 02/19/2013] [Indexed: 10/27/2022]
|
12
|
Saab A, Gali-Muhtasib H, Maietti S, Grandini A, Rossi D, Lampronti I, Gallerani E, Fabbri E, Gambari R. Comparative antiproliferative activities of wood and seeds essential oils ofJuniperus oxycedrusL. against K562 human chronic myelogenous leukemia cells. Journal of Essential Oil Research 2013. [DOI: 10.1080/10412905.2013.829006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C, Ongarello S, Liedert B, Gallerani E, Beck J, Omlin A, Sessa C, Quaratino S, Stupp R, Gnad-Vogt US, Speiser DE. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5. [PMID: 23294527 PMCID: PMC3551760 DOI: 10.1186/1479-5876-11-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2012] [Accepted: 12/21/2012] [Indexed: 12/03/2022] Open
Abstract
Background EMD 521873 (Selectikine or NHS-IL2LT) is a fusion protein consisting of modified human IL-2 which binds specifically to the high-affinity IL-2 receptor, and an antibody specific for both single- and double-stranded DNA, designed to facilitate the enrichment of IL-2 in tumor tissue. Methods An extensive analysis of pharmacodynamic (PD) markers associated with target modulation was assessed during a first-in-human phase I dose-escalation trial of Selectikine. Results Thirty-nine patients with metastatic or locally advanced tumors refractory to standard treatments were treated with increasing doses of Selectikine, and nine further patients received additional cyclophosphamide. PD analysis, assessed during the first two treatment cycles, revealed strong activation of both CD4+ and CD8+ T-cells and only weak NK cell activation. No dose response was observed. As expected, Treg cells responded actively to Selectikine but remained at lower frequency than effector CD4+ T-cells. Interestingly, patient survival correlated positively with both high lymphocyte counts and low levels of activated CD8+ T-cells at baseline, the latter of which was associated with enhanced T-cell responses to the treatment. Conclusions The results confirm the selectivity of Selectikine with predominant T-cell and low NK cell activation, supporting follow-up studies assessing the clinical efficacy of Selectikine for cancer patients.
Collapse
Affiliation(s)
- Julien Laurent
- Division of Experimental Oncology, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D’Incalci M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2013; 49:290-6. [DOI: 10.1016/j.ejca.2012.09.009] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2012] [Revised: 09/06/2012] [Accepted: 09/08/2012] [Indexed: 11/16/2022]
|
15
|
Gallerani E, Cathomas R, Sessa C, Digena T, Bartosek AA, Zotto LD, von Moos R. A Phase I Study of the Oral Platinum Agent Satraplatin in Combination with Oral Vinorelbine in Patients with Advanced Solid Malignancies. ACTA ACUST UNITED AC 2013; 36:40-5. [DOI: 10.1159/000346671] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
16
|
Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci MR, Liedert B, Kramer D, Laurent J, Speiser DE, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2012; 49:35-44. [PMID: 22918078 DOI: 10.1016/j.ejca.2012.07.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2012] [Revised: 06/26/2012] [Accepted: 07/11/2012] [Indexed: 11/25/2022]
Abstract
BACKGROUND EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. METHODS Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3 weeks. A subgroup of patients also received 300 mg/m(2) cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). RESULTS Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to 0.9 mg/kg, and nine were treated at doses of 0.45 and 0.6 mg/kg in combination with cyclophosphamide. A dose-dependent linear increase of peak serum concentrations and area under curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9 mg/kg dose-level; the MTD was 0.6 mg/kg. Rash and flu-like symptoms were the most frequent side-effects. No severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded. No objective tumour responses, but long periods of disease stabilisation were observed. Transient and non-neutralising Selectikine antibodies were detected in 69% of patients. CONCLUSIONS The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6 mg/kg. The recommended phase II dose was 0.45-0.6 mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.
Collapse
|
17
|
Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861-8. [PMID: 22753904 DOI: 10.1200/jco.2011.40.9243] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
PURPOSE Skin toxicity in patients receiving cetuximab has been associated positively with clinical outcome in several tumor types. This study investigated the effect of cetuximab dose escalation in patients with irinotecan-refractory metastatic colorectal cancer who had developed no or mild skin reactions after 21 days of treatment at the standard dose. This article reports clinical and pharmacokinetic (PK) data. PATIENTS AND METHODS After 21 days of standard-dose cetuximab (400 mg/m(2) initial dose, then 250 mg/m(2) per week) plus irinotecan, patients with ≤ grade 1 skin reactions were randomly assigned to standard-dose (group A) or dose-escalated (to 500 mg/m(2) per week; group B) cetuximab. Patients with ≥ grade 2 skin reactions continued on standard-dose cetuximab plus irinotecan (group C). RESULTS The intent-to-treat population comprised 157 patients. PK profiles reflected the dose increase and were predictable across the dose range investigated. Weekly cetuximab doses of up to 500 mg/m(2) were well tolerated, and grade 3 and 4 adverse events were generally comparable between treatment groups. Dose escalation (n = 44) was associated with an increase in skin reactions ≥ grade 2 compared with standard (n = 45) dosing (59% v 38%, respectively). Dose escalation, compared with standard dosing, showed some evidence for improved response rate (30% v 16%, respectively) and disease control rate (70% v 58%, respectively) but no indication of benefit in relation to overall survival. In an exploratory analysis, dose escalation seemed to increase response rate compared with standard dosing in patients with KRAS wild-type but not KRAS mutant tumors. CONCLUSION Cetuximab serum concentrations increased predictably with dose. Higher dose levels were well tolerated. The possible indication for improved efficacy in the dose-escalation group warrants further investigation.
Collapse
|
18
|
Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TRJ, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol 2012; 30:996-1004. [PMID: 22355064 DOI: 10.1200/jco.2010.34.5074] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The appropriate selection of patients for early clinical trials presents a major challenge. Previous analyses focusing on this problem were limited by small size and by interpractice heterogeneity. This study aims to define prognostic factors to guide risk-benefit assessments by using a large patient database from multiple phase I trials. PATIENTS AND METHODS Data were collected from 2,182 eligible patients treated in phase I trials between 2005 and 2007 in 14 European institutions. We derived and validated independent prognostic factors for 90-day mortality by using multivariate logistic regression analysis. RESULTS The 90-day mortality was 16.5% with a drug-related death rate of 0.4%. Trial discontinuation within 3 weeks occurred in 14% of patients primarily because of disease progression. Eight different prognostic variables for 90-day mortality were validated: performance status (PS), albumin, lactate dehydrogenase, alkaline phosphatase, number of metastatic sites, clinical tumor growth rate, lymphocytes, and WBC. Two different models of prognostic scores for 90-day mortality were generated by using these factors, including or excluding PS; both achieved specificities of more than 85% and sensitivities of approximately 50% when using a score cutoff of 5 or higher. These models were not superior to the previously published Royal Marsden Hospital score in their ability to predict 90-day mortality. CONCLUSION Patient selection using any of these prognostic scores will reduce non-drug-related 90-day mortality among patients enrolled in phase I trials by 50%. However, this can be achieved only by an overall reduction in recruitment to phase I studies of 20%, more than half of whom would in fact have survived beyond 90 days.
Collapse
Affiliation(s)
- David Olmos
- The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncol 2011; 50:1105-10. [PMID: 21184645 DOI: 10.3109/0284186x.2010.543697] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND The broad spectrum of antitumor activity of both the oral platinum analogue satraplatin (S) and capecitabine (C), along with the advantage of their oral administration, prompted a clinical study aimed to define the maximum tolerated dose (MTD) of the combination. PATIENTS AND METHODS Four dose levels of S (mg/m(2)/day) and C (mg/m(2)/day) were evaluated in adult patients with advanced solid tumors: 60/1650, 80/1650, 60/2000, 70/2000; a course consisted of 28 days with sequential administration of S (days 1-5) and C (days 8-21) followed by one week rest. RESULTS Thirty-seven patients were treated, 24 in the dose escalation and 13 in the expansion phase; at the MTD, defined at S 70/C 2000, two patients presented dose limiting toxicities: lack of recovery of neutropenia by day 42 and nausea with dose skip of C. Most frequent toxicities were nausea (57%), diarrhea (51%), neutropenia (46%), anorexia, fatigue, vomiting (38% each). Two partial responses were observed in platinum sensitive ovarian cancer and one in prostate cancer. CONCLUSION At S 70/C 2000 the combination of sequential S and C is tolerated with manageable toxicities; its evaluation in platinum and fluorouracil sensitive tumor types is worthwhile because of the easier administration and lack of nephro- and neurotoxicity as compared to parent compounds.
Collapse
Affiliation(s)
- Elisa Gallerani
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Sessa C, von Moos R, Digena T, Del Conte G, Viganö L, Gallerani E, Cathomas R, Fasolo A, Schneider D, Gianni L. 1257 POSTER Phase I Safety and Tolerability Study of Olaparib (AZD2281) in Combination With Liposomal Doxorubicin (PLD) in Patients With Advanced Metastatic Solid Tumours. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70869-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
21
|
Fasolo A, Del Conte G, Calderone RG, Gallerani E, Hagner N, Barbieri P, Luraghi L, Pace S, Capocasa F, Coceani N, Maccioni E, Hess D, Sessa C, Gianni L. Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Cassier PA, Moreno Garcia V, Gomez-Roca C, Olmos D, Morales R, Del Conte G, Gallerani E, Brunetto A, Schoffski P, Marsoni S, Schellens JHM, Penel N, Voest EE, Evans TRJ, Plummer R, Wilson RH, Soria J, Tabernero J, Verweij J, Kaye SB. Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3084] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Sessa C, Gallerani E, Del Conte G, Christinat A, Perotti A, Lardelli P, Kahatt CM, Florez A, Fernandez C, Miani M, Gianni L. Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Gross S, Lennerz V, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Zieschang J, Forssmann U, Wölfel T, Kaempgen E. Abstract 5516: Therapeutic vaccination with the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-5516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Survivin is a promising tumor-associated antigen for cancer immunotherapy that fulfills two major criteria for this purpose: (1) tumor cells depend on the actions of survivin (inhibition of apoptosis, unrestricted proliferation and angiogenesis); and (2) the protein has demonstrated immunogenicity in patients with different cancers. Here we report results of a first-in-man Phase I study with EMD640744, a cocktail of survivin-derived partially modified HLA class I-restricted peptides in Montanide® ISA 51 VG.
Methods: This multicenter, open-label, parallel group, randomized study compared the immunologic efficacy, safety, tolerability and clinical activity of three dosages of EMD640744 (30, 100, or 300 µg) in patients with different types of metastatic or locally advanced solid tumors who were positive for at least one relevant HLA antigen (A1, A2, A3, A24, B7). Patients received weekly s.c. injections of EMD640744 for 8 weeks followed by injections every 4 weeks until tumor progression. For the assessment of the primary endpoint, PBMC samples were prepared at baseline and after 4, 8, 12, 16, and 17 weeks. Peptide-specific T cell responses were analyzed by IFN-γ ELISpot. As a secondary analysis, peptide/HLA-multimer staining was performed. Frequencies of CD8+ T cells specific for patient-relevant single HLA-restricted peptides and EMD640744 were determined ex vivo and after short-term in vitro presensitization with EMD640744. Native homologues of modified vaccination peptides were also included in the analysis.
Results: Of 66 patients screened, 53 were treated, and a majority was eligible for response analysis: 38 patients were analyzed by ELISpot and 42 by multimers, with positive ex vivo responses observed in 7 (18%) and 14 (33%) patients, respectively. Combining ex vivo data with results after in vitro stimulation, T cell responses were detected in 14 (37%) and 31 (74%) patients by ELISpot and multimer analysis, respectively. Multimer staining revealed a de novo induction of T cells against survivin peptides in at least 16 patients (38%) whereas pre-existent responses were seen in only 4 patients (10%). T cell responses were detected in all dose groups with similar frequencies. Five out of 10 HLA-A2+ patients reacting against the modified A2-binding peptide in ELISpot assays showed responses against its native homologue. The best tumor response according to RECIST was stable disease in 28% of patients. The most frequent treatment-related adverse events (AEs) were Grade 1-2 local injection site reactions and 2 patients experienced treatment-related Grade 3 AEs (granuloma at injection site and thrombosis).
Conclusion: Vaccination with EMD640744 was safe and well tolerated and elicited de novo T cell responses against survivin peptides, demonstrating immunological efficacy of EMD640744 in cancer patients.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5516. doi:10.1158/1538-7445.AM2011-5516
Collapse
Affiliation(s)
- Volker Lennerz
- 1III. Medizinische Klinik und Poliklinik, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
| | - Stefanie Gross
- 2Department of Dermatology, Immunomonitoring – Group, Erlangen, Germany
| | - Elisa Gallerani
- 3IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Cristiana Sessa
- 3IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Nicolas Mach
- 4Division d'Oncologie, Hôpitaux Universitaires de Genève (HUG), Genève, Switzerland
| | - Steffen Boehm
- 5Onkologie/Hämatologie, Kantonsspital, St. Gallen, Switzerland
| | - Dagmar Hess
- 5Onkologie/Hämatologie, Kantonsspital, St. Gallen, Switzerland
| | - Lotta von Boehmer
- 6Department of Oncology, University Hospital Zurich, Zurich, Switzerland
| | - Alexander Knuth
- 6Department of Oncology, University Hospital Zurich, Zurich, Switzerland
| | - Adrian Ochsenbein
- 7Klinik und Poliklinik für Medizinische Onkologie, Inselspital, Bern, Switzerland
| | | | | | | | - Thomas Wölfel
- 1III. Medizinische Klinik und Poliklinik, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
| | - Eckhart Kaempgen
- 2Department of Dermatology, Immunomonitoring – Group, Erlangen, Germany
| |
Collapse
|
26
|
Sessa C, Martinelli G, Hess D, Delmonte A, Noberasco C, Sammassimo S, Gallerani E, Marsoni S, Camboni G, de Braud F. 379 A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM). EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72086-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
27
|
Cresta S, Sessa C, Del Conte G, Locatelli A, Gallerani E, Fiorentini F, Scaburri A, Pacciarini MA, Alzani R, Gianni L. Phase l study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Gallerani E, Delord J, Schoffski P, Vergote IB, Trillet-Lenoir VN, Maur M, Jannuzzo MG, Petroccione A, Locatelli G, Lorusso D. Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Garassino MC, Michetti G, Lo Dico M, Califano R, Aglione S, Borgonovo K, Mancuso A, Galetta D, Gallerani E, Collovà E, Torri V. Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL): A retrospective analysis of 166 patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19093 Background: Patients with SCLC progressed after first-line chemotherapy (FL) have a poor prognosis and the evidence of a benefit of SL is still limited.This retrospective analysis evaluates the clinical outcomes of patients who received a SL treatment after failure of a FL for SCLC Methods: Retrospectively we reviewed 166 consecutive patients who failed a FL and received a second or third-line treatment, between 1993 and 2008 in 17 institutions. We divided patients for analysis in four subgroups, according to the type of SL administered: 1) Platinum-based (P) rechallenge 2) Non-platinum-based polichemotherapy 3) Non-topotecan monochemotherapy 4) topotecan monochemotherapy. Our endpoints were Overall survival (OS), Progression free survival (PFS) and Response Rate. Survival curves were designed with Kaplan-Meier method and Cox proportional hazard model was used for investigating factors which influence survival Results: Median age was 63 (range 25–86). Median OS from the SL was 6.2 months and PFS 2.9. 163 patients received a platinum based chemotherapy as FL, among them 67% obtained a response (CR=14%, PR=53.7%) and 19% had a progressive disease. 74% of patients had a PS 0–1 when started on SL. Moreover, 50 patients underwent also a third-line chemotherapy. Of the 23 CR at FL, 7 patients achieved a response in SL(30%), of the 85 PR only 19 (22%) and of the PD+SD only 6 (16%) (test for trend p=.03). No statistical differences among regimens groups were found; however, patients rechallenged with P went better then others when a long PFS in FL was demonstrated (p=.02) Conclusions: The clinical benefit of SL therapy for SCLC is poor and strictly dependent on response and on duration of response with FL treatment. Our retrospective analysis confirms that median OS for patients receiving SL is about 6 months and median PFS 2.9 months. A rechallenge with platinum should be the best options in patients with a long PFS in FL. Single agent topotecan, the most investigated agent in the literature, did not show evidence of superiority against other chemotherapy regimens No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. C. Garassino
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - G. Michetti
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - M. Lo Dico
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - R. Califano
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - S. Aglione
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - K. Borgonovo
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - A. Mancuso
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - D. Galetta
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - E. Gallerani
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - E. Collovà
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| | - V. Torri
- Fatebenefratelli and Opthalmic Hospital, Milano, Italy; Ospedali Riuniti, Bergamo, Italy; Ospedale di Livorno, Livorno, Italy; Christie Hospital, Manchester, United Kingdom; Ospedale Vimercate, Vimercate, Italy; Fatebenefratelli and Ophtalmic Hospital, Milano, Italy; San Camillo Hospital, Roma, Italy; Istituto Tumori Bari, Bari, Italy; South Switzerland Hospital, Bellinzona, Switzerland; Ospedale Civile, Legnano, Italy; Istituto di Ricerche Mario Negri, Milano, Italy
| |
Collapse
|
30
|
Hess D, Boehm S, Delmonte A, Gallerani E, Barbieri P, Pace S, Carminati P, Marsoni S, Coceani N, Sessa C. Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2570 Background: Namitecan is a new water-soluble camptothecin analogue which showed high antitumor activity in preclinical models. Aim of this trial was to determine safety, PK profile and activity in adult patients with advanced solid tumors. Methods: The dose escalation started at 2.5 mg i.v. on days 1 and 8 of a 21 day cycle (D1, D8 Q21D) and increased according to 3+3 cohort design depending on the observed toxicity. Dose limiting toxicity (DLT) definitions were: ANC <0.5x109/L for >5 days; PLT ≥ Grade 3 (CTC V3); grade ≥2 liver/renal toxicity not recovered by D22; any non-hematologic toxicity ≥ Grade 3; D8 dose skipping due to toxicity. Maximum tolerated dose (MTD) and recommended dose (RD) were the primary end-points. Blood and urine samples were collected at cycle 1 for PK evaluation. Results: 31 pts (11 endometrial ca., 5 CRC, 5 ovarian ca., 2 NSCLC, 8 other) have been included, with 6 dose levels evaluated (2.5; 5; 10; 15; 17.5 and 20 mg). 17.5 mg was introduced later when 2/7 DLTs at 20 mg were observed (ANC G4>5days, one with D8 skipping). At 17.5mg 2/4 pts experienced DLTs (ANC G4; D8 skipped). Uncomplicated neutropenia and thrombocytopenia were the most relevant G3/4 hematological toxicities. Other toxicities were mild or moderate asthenia, fatigue and alopecia. The MTD was defined at 17.5 mg and the RD was 15 mg. Stable disease ≥ 6 cycles was recorded in 6 pts (2 stable diseases ≥ 10 cycles). PK was linear and data suggest an entero-hepatic recirculation. No metabolites were found in plasma and the product resulted poorly excreted into urine. Conclusions: The MTD and RD of D1, D8 Q21D schedule have been identified. The study will continue with the evaluation of MTD and RD of a single administration per cycle (D1 Q21D), to optimize the schedule of treatment. [Table: see text]
Collapse
Affiliation(s)
- D. Hess
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - S. Boehm
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - A. Delmonte
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - E. Gallerani
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - P. Barbieri
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - S. Pace
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - P. Carminati
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - S. Marsoni
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - N. Coceani
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| | - C. Sessa
- Kantonsspital St. Gallen, St. Gallen, Switzerland; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Sigma Tau Research Switzerland S.A., Mendrisio, Switzerland; Sigma Tau, Pomezia, Italy; SENDO, Milano, Italy
| |
Collapse
|
31
|
Sessa C, Hess D, Bauer J, Droege C, Gallerani E, Miani M, Tinazzi A, Krieter O, Angst R, Nay C. Phase I study of the oral platinum agent satraplatin (S) in sequential combination with capecitabine (C) in patients with advanced solid tumours. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2560] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Affiliation(s)
- Elisa Gallerani
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Michele Ciriolo
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Chiara Rossini
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Franco Cavalli
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
33
|
Consales G, Campiglia L, Michelagnoli G, Gallerani E, Rinaldi S, Del Pace S, De Gaudio AR. Acute left ventricular dysfunction due to Tako-tsubo syndrome after induction of general anesthesia. Minerva Anestesiol 2007; 73:655-658. [PMID: 18046297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Tako-tsubo cardiomyopathy is a recently described form of transient ventricular dysfunction that is not associated with coronary vessels obstruction, although its clinical manifestations are often similar to those of myocardial ischemia. This syndrome is possibly due to an excess of catecholamines, and it is associated with emotional and physical stress and surgery. However, the pathophysiological relation to anaesthesia has not yet been clarified. We report a case of Tako-tsubo cardiomyopathy that ensued immediately after induction of general anaesthesia for elective surgery in a patient submitted to laparoscopic cholecystectomy. The patient was first treated as if affected by myocardial ischemia, but a rapidly performed emergency coronary angiography showed normal epicardial coronary vessels with a significant reduction of left ventricular function. The coronary angiography ruled out the diagnosis of typical myocardial ischemia and allowed for the arrival at the correct diagnosis. The transient ventricular ballooning was attributed to the recently described Tako-tsubo syndrome. Prompt treatment allowed control of symptoms, and the patient was safely treated and discharged on day 15. Although it is difficult to identify the cause of this syndrome, it may be argued that, during general anaesthesia and particularly at induction, the imperfect control of catecholamine excess may induce cardiac damage in predisposed subjects.
Collapse
Affiliation(s)
- G Consales
- Section of Anaesthesia and Intensive Care, Department of Critical Care, University of Florence, Florence, Italy.
| | | | | | | | | | | | | |
Collapse
|
34
|
Humblet Y, Peeters M, Gelderblom H, Vermorken J, Viret F, Glimelius B, Ciardiello F, Gallerani E, Kisker O, van Cutsem E. 3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study. European Journal of Cancer Supplements 2007. [DOI: 10.1016/s1359-6349(07)70945-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Pacey SC, Wilson R, Walton M, Eatock M, Moreno-Farre J, Gallerani E, Davergne V, Raynaud F, Workman P, Judson I. A phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17- DMAG, alvespimycin) administered weekly. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3568] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3568 Background: The geldanamycin analogue 17-DMAG inhibits the ATPase activity of HSP90, thus altering client protein & chaperone interactions and targeting client proteins for degradation. The plethora of oncogenic HSP90 client proteins offers the potential of combinatorial blockade across multiple, cancer causing signalling pathways in cancer. Methods: 17-DMAG was administered weekly to patients with advanced, solid tumours using a dose-doubling 3 + 3 Phase I design. The pharmacokinetic (PK) and pharmacodynamic (PD) analyses undertaken were validated to comply with U.K clinical trial legislation. Results: 10 patients, 7 male and 3 female with a mean age of 60 years (range 38 - 78) have received 107 infusions (mean 10.7 weeks, range 2 - 30) at dose levels of 2.5mg/m2, 5mg/m2 & 20mg/m2. No dose-limiting or drug related grade 3 or 4 toxicity has occurred in 9 patients eligible for toxicity assessment. A linear relationship exists between dose and AUC and Cmax (see table ). Hsp72 induction and CDK4 depletion (consistent with HSP90 inhibition) have been detected at doses of 20mg/m2 in peripheral blood mononuclear cells. A confirmed partial response (by PSA and RECIST) has occurred in a patient with hormone refractory prostate cancer (HRPC). Conclusions: We have shown linear PK for 17-DMAG up to 20mg/m2. No dose-limiting toxicity has been encountered. A robust biologically active dose has not been reached but evidence of the pharmacological signature of HSP90 inhibition has been detected in surrogate tissue and a confirmed PR seen in a patient with HRPC. These data support dose escalation to 40mg/m2 and paired tumor biopsies will be taken to further define the PK-PD-clinical relationships. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. C. Pacey
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - R. Wilson
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - M. Walton
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - M. Eatock
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - J. Moreno-Farre
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - E. Gallerani
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - V. Davergne
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - F. Raynaud
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - P. Workman
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| | - I. Judson
- Institute of Cancer Research, Belmont Surrey, United Kingdom; Queen’s University, Belfast, United Kingdom; The Royal Marsden Foundation NHS Trust, Sutton, United Kingdom; Cancer Research UK, London, United Kingdom
| |
Collapse
|
36
|
Gallerani E, Yap TA, Lopez A, Coronado C, Shaw H, Florez A, de las Heras B, Cortes-Funes H, de Bono J, Paz-Ares L. Phase I study of PM00104, a novel cytotoxic anti-cancer drug, administered to patients with advanced solid tumors or lymphoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2517] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2517 Background: PM00104 (Zalypsis [Z]) is a novel synthetic alkaloid related to the marine compounds Jorumycin and the family of Renieramycins. Preliminary analyses of its mechanisms of action suggest effects on the cell cycle, DNA binding properties, as well as transcriptional inhibition. Z has shown antitumor activity in vitro (IC50 =10-8 M) and in xenografts models, and an acceptable toxicology profile. Methods: Patients (pts) with advanced cancers or lymphoma were enrolled to determine the safety, tolerability, maximum tolerated dose (MTD), recommended dose (RD), pharmacokinetics (PK) and antitumor activity of Z administered as a 1- hour IV infusion every 3 weeks. Sequential cohorts of 3–6 pts received the following doses: 0.225, 0.45, 0.9, 1.8, 3.0 and 3.6 mg/m2. Results: 27 pts were treated (19 M; median age: 58, range: 39–79; ECOG PS =2). 2 of 6 pts at 3.6 mg/m2 experienced dose-limiting toxicities (DLT), defining the MTD; 1 pt with colorectal cancer with extensive liver metastases developed grade 4 thrombocytopenia and neutropenia, grade 3 transaminase elevation, and grade 4 troponin I rise without cardiac symptoms or electrocardiogram alterations. These toxicities all resolved. Another pt with adrenal carcinoma developed grade 3 nausea, vomiting and asthenia despite anti-emetics, which resolved with dexamethasone 2 days after infusion. Other toxicities were =grade 2 and included: nausea, vomiting, transient transaminase elevation and asthenia at doses =0.225 mg/m2 and myelosuppression (neutropenia and leukopenia) at doses =3.0 mg/m2. No DLTs were seen in 6 pts at a dose of 3.0 mg/m2, establishing this dose as the RD. 3 more pts were added to complete the expanded cohort at this RD. To date, 2 pts have SD lasting >3 months. PK data indicate that drug AUC and Cmax increase proportionally across the dose range until doses =3.0 mg/m2, when a disproportionate increase in AUC and Cmax was seen. Z has a long half-life (=50 hours) and wide volume of distribution (Vss ∼500 l/m2). Conclusions: Z has a favorable safety profile. The MTD on this schedule has been established at 3.6 mg/m2. Alternative schedules are being evaluated to try and increase dose intensity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Gallerani
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - T. A. Yap
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - A. Lopez
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - C. Coronado
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - H. Shaw
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - A. Florez
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - B. de las Heras
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - H. Cortes-Funes
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - J. de Bono
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| | - L. Paz-Ares
- Royal Marsden Hospital, Sutton, United Kingdom; Hospital Universitario 12 de Octubre, Madrid, Spain; Pharma Mar, S.A.U., Madrid, Spain
| |
Collapse
|
37
|
Reid AH, Tang A, Spicer J, Gallerani E, Mears D, Settatree S, Yap TA, Puchalski T, Harrison M, De-Bono JS. An open, pharmacokinetic (PK) and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14140] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14140 Background: AZD2171 is an oral, highly potent and selective VEGF signaling inhibitor in clinical development. Methods: Patients with solid metastatic tumors received a single radiolabeled oral dose of 14C- AZD2171 45 mg; blood samples and all excretions were collected for evaluating the PK and metabolic profiles. After sufficient radioactivity recovery, patients started once-daily oral dosing with AZD2171 30 mg. The primary objective of the study was to determine the rates and routes of excretion of AZD2171 using 14C-AZD2171. Efficacy (RECIST), safety and tolerability were secondary objectives. The potential effects of AZD2171 on DCE-CT vascular parameters were also explored. Results: Six patients received treatment and remained on study for 64–171 days. In 5/6 patients, the amount of radioactivity recovered in the urine and feces samples within 168-hours post- dosing ranged from 84.8–93.0%; the analogous amount in the remaining patient was only 34.1%. In all patients, mean radioactivity recovered was 58.8% in feces and 20.8% in urine. Radioactivity appeared to be confined to plasma. Three patients (2 renal cell carcinoma; 1 mesothelioma) had a best RECIST response of stable disease (SD); 1 patient had a confirmed reduction in max tumor diameter of 10% to <30%. Two patients had progressive disease and 1 patient was non-evaluable. The most common adverse events (AEs) were diarrhea (n=5) and hypertension (n=3); no grade 3 or 4 AEs occurred more than once. There was evidence of reductions in DCE-CT parameters post treatment, particularly perfusion, permeability surface product (PSP) and positive enhancement integral. For each of these parameters, a decrease from baseline outside the baseline reference range was recorded for 3 patients (including 2 with SD) at 1 month after the start of daily dosing of AZD2171. Overall, within-patient variability (W-PV) was generally low for all DCE-CT parameters measured and was consistently lower than between-patient variability. The W-PV was largest for PSP (18%) and lowest for mean transit time (7%). Conclusions: The primary route of AZD2171 elimination appears to be hepatic. AZD2171 was well tolerated and clinically meaningful disease stabilization was seen. Changes in tumor vascular parameters were detected by DCE-CT. [Table: see text]
Collapse
Affiliation(s)
- A. H. Reid
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - A. Tang
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - J. Spicer
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - E. Gallerani
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - D. Mears
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - S. Settatree
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - T. A. Yap
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - T. Puchalski
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - M. Harrison
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| | - J. S. De-Bono
- Royal Marsden Hospital, London, United Kingdom; AstraZeneca, Wilmington, DE; AstraZeneca, Macclesfield, United Kingdom
| |
Collapse
|
38
|
Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, Marone C, Cavalli F. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 2006; 77:527-9. [PMID: 17042766 DOI: 10.1111/j.1600-0609.2006.00758.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a haematological syndrome characterised by a dramatic onset requiring an urgent treatment with plasma exchange (PE). However, the prognosis is still dismal for PE related complications, a rate of failure and remarkable frequencies of relapse. TTP post transplantation is largely described as an outstanding, unusual complication of allogenic transplantation, but it is rarely mentioned after autologous transplantation. We describe a 62-year-old Caucasian patient who presented with TTP, accompanied by renal failure, after an autologous transplantation for multiple myeloma. PE together with hemodialysis was rapidly initiated but without any benefit. Since empirical administration of Rituximab, anti CD20 monoclonal antibody,was reported to be effective, we administered four courses of Rituximab inducing a complete remission of TTP and subsequently of the renal failure. This response to Rituximab in TTP post transplantation is suggestive of a possible implication of B-lymphocytes in the pathogenesis of TTP and it paves the way for an investigational approach in this settings.
Collapse
Affiliation(s)
- Elisa Gallerani
- Department of Oncology, Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Perotti A, Maur M, Viganò L, Gallerani E, Angst R, Albanell J, Sessa C, Laliberte R, Marsoni S, Gianni L. Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3065] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3065 Background: AP23573 is a novel mTOR inhibitor with anti-tumor activity in Phase1 and 2 trials. In vitro, AP23573 is at least additive with chemotherapy agents including 5FU. CAPE is activated to 5FU by thymidine phosphorylase which may be highly expressed in tumors and correlates with progression through angiogenic mechanisms controlled by mTOR. Given the potential for a positive interaction, this trial studied the combination of AP23573 and CAPE in adult patients with solid tumors. Methods: Starting doses were: AP23573 25 mg i.v. on Days 1, 8, and 15 of a 28-day cycle, and CAPE 1650 mg/m2 p.o. daily on Days 1–14. Planned PK and PD studies include analysis of plasma VEGF, PBMC, skin, and tumor samples for effects on pathways associated with mTOR and on the metabolism of CAPE and fluoropyrimidines. Dose limiting toxicity (DLT) was defined as: febrile neutropenia; neutrophils <500x106/L for ≥ 5 days; ≥ Grade 3 (CTC) thrombocytopenia; non-haematological toxicities ≥ Grade 2 (diarrhea, cardiac or renal); or missing two consecutive weekly doses due to any toxicity. Results: 15 patients have been treated. Three dose levels of weekly AP23573 (25, 37.5 and 50 mg) were completed without DLT. Treatment-related toxicity was mostly mild or moderate (≤ grade 2), with mucositis/stomatitis the most frequent. Anti-tumor activity included a partial response in a case of endometrial cancer, and stable disease > 4 months in 3 cases (1 renal, 1 uterine and 1 head & neck cancer). AP23573 did not affect the PK of CAPE or 5FU but a trend toward a decreased exposure to the catabolite 5-FuH2 was apparent in the presence of AP23573. In keeping with this observation, the activity of dihydro-pyridine-dehydrogenase gradually decreased to 60% of that before AP23573. This decrease was not associated with reduced tolerability. Conclusions: The combination of AP23573 with CAPE is safe with initial indications of anti-tumor activity. This is the first description of a feasible combination of an mTOR inhibitor with an anti-metabolite. Additional dose levels of AP23573 (75 mg) and CAPE (1850 mg/m2/day) are ongoing and PK and PD studies are continuing. [Table: see text]
Collapse
Affiliation(s)
- A. Perotti
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - M. Maur
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - L. Viganò
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - E. Gallerani
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - R. Angst
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - J. Albanell
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - C. Sessa
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - R. Laliberte
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - S. Marsoni
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| | - L. Gianni
- Istituto Nazionale dei Tumori, Milano, Italy; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Hospital del Mar IMAS, Barcelona, Spain; ARIAD Pharmaceuticals, Inc., Cambridge, MA; Southern Europe New Drug Organization (SENDO), Milan, Italy
| |
Collapse
|
40
|
Gallerani E, Cresta S, Tosi D, Sessa C, Capri G, Catapano CV, Bertoni F, Marsoni S, Tursi J, Gianni L. A phase I-II and pharmacodynamic (PD) study of the combination of the proteasome inhibitor bortezomib (B) and paclitaxel (P) in patients with taxane-sensitive solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13029 Background: Proteasome inhibition blocks the chemotherapy-induced activation of NF-кB increasing chemosensitivity to anticancer agents due to increased apoptosis. NF-кB is frequently aberrantly activated in primary human carcinomas and over-expressed in aggressive breast cancer lines1 supporting the rationale for combining B with P. We designed a phase I-II and PD trial to determine the recommended dose (RD) of the B&P combination, to screen for antitumor activity in patients with potentially taxane-sensitive tumors, to search for drug-induced changes and to identify potential surrogate markers of drug activity and toxicity in peripheral blood mononuclear cells (PBMC). Methods: Eligibility included ECOG performance status < 2, neurotoxicity < 2 and adequate organ functions. Treatment was given Q21 days: B on days 1,4, 8 and 11 and P on days 1 and 8. PBMC for gene expression profiling have been collected on day 1 and 4 before and after therapy. RECIST for response was applied. Results: Twenty-nine patients (20 female, median age 60 yrs) were accrued and 25 are evaluable (breast cancer: 13, ovarian cancer: 7, prostate cancer 1, other 4) ; 16 pts were treated in 4 escalation levels and the RD defined respectively at 1.3 mg/m2/dose & 100 mg/m2/dose for B&P. Neurotoxicity was the main toxicity (G1 36%, G2 20% and 1 case G3) requiring treatment discontinuation in 2 pts at cy 6 & 7. Other toxicities (all grades) were nausea and vomiting (68%), diarrhea (56%, G3 12%), alopecia (52%), asthenia (36%, G2 4%), and myalgia (32%, G2 8%). Antitumor activity consisted of 3 PR in pts with ovarian cancer lasting respectively 14, 8+ and 16 wks; 2 PRs in pts with breast cancer (12+ wks,14+ wks) and 1 PR in a pt with prostate cancer. Conclusions: Thus far the regimen has acceptable toxicity with evidence of antitumor activity. The trial will continue until accrual of four additional patients as planned. Footnotes 1 Adams J Current Opin Oncol 2002, 14:628–634. [Table: see text]
Collapse
Affiliation(s)
- E. Gallerani
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - S. Cresta
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - D. Tosi
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - C. Sessa
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - G. Capri
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - C. V. Catapano
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - F. Bertoni
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - S. Marsoni
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - J. Tursi
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| | - L. Gianni
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Istituto Nazionale dei Tumori, Milan, Italy; Southern Europe new drugs Organization (SENDO), Milan, Italy
| |
Collapse
|
41
|
Pagani O, Ruggeri M, Rusca T, Graffeo R, Gallerani E, Locatelli M, Conti Beltraminelli M, Longhi S, Mazzucchelli L, Goldhirsch A. Does HER2/neu expression affect adjuvant treatment choices in routine clinical practice? J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10667 Background: HER2/neu (HER2) amplification is a recognized independent prognostic and predictive factor. We retrospectively examined the correlation between HER2 expression and adjuvant therapy in patients (pts) with early breast cancer (EBC) at our Institution (IOSI). Materials and Methods: From January 2003, 326 consecutive pts with EBC have been treated at IOSI and all clinical and pathological data have been prospectively collected into a specifically designed data base (CARMA). HER2 expression was assessed by the c-erbB-2 oncoprotein antibody (NCL-L-CB11) in 309 pts (95%). FISH was not routinely performed. Endocrine responsiveness (ER+) is defined as Er and/or PgR expression by immunohistochemistry. Results: Overall, 58 pts (19%) had HER2+ disease. FISH was performed in 15 pts (24%) with doubtful antibody overexpression (2+) and did not confirm HER2 amplification in 4 cases (27%). Nodal involvement was not assessed in 1 HER2+ (2%) and in 12 HER2- pts (5%) due to advanced age. Menopausal status did not differ in HER2 positive and negative pts (29% and 27% premenopausal pts, respectively). The distribution of adjuvant chemotherapy (CT) according to tumour characteristics in HER2 positive and negative pts was as follows: An anthracycline-containing regimen was chosen in 88% of HER2+ pts receiving adjuvant CT as compared to 70% of HER2- pts. Outside of a clinical trial adjuvant Tamoxifen was given to 57% of HER2+/ER+ pts as compared to 75% of HER2−/ER+ pts. Conclusions: Overall, HER2+ pts showed less endocrine responsiveness (64% versus 88%) and more extensive nodal involvement (43% versus 30% with >3 positive nodes) as compared to HER2− pts. A greater proportion of HER2+ women received adjuvant CT, irrespective of other prognostic and predictive factors. In particular, a significant higher proportion of HER2+ pts with minimal nodal involvement (1–3 positive nodes) and ER+ disease received CT as compared to the equivalent HER2- subset (45% versus 26%, respectively). [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Pagani
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - M. Ruggeri
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - T. Rusca
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - R. Graffeo
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - E. Gallerani
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - M. Locatelli
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - M. Conti Beltraminelli
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - S. Longhi
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - L. Mazzucchelli
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| | - A. Goldhirsch
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Mendrisio, Switzerland; Institute of Pathology of Southern Switzerland, Locarno, Switzerland; Oncology Institute of Southern Switzerland, Lugano, Switzerland
| |
Collapse
|
42
|
|
43
|
de Braud F, Sessa C, Gallerani E, Curigliano G, Cipolla C, Columbo A, Gallino A, Schackleton G, Zilocchi C, Chadjaa M. Phase I dose escalation study of SR271425 administered as 24-hour intravenous continuous infusion in patients with refractory solid tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. de Braud
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - C. Sessa
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - E. Gallerani
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - G. Curigliano
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - C. Cipolla
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - A. Columbo
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - A. Gallino
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - G. Schackleton
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - C. Zilocchi
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| | - M. Chadjaa
- Inst Europeo di Oncologia, Milano, Italy; Oncologia Institute of Southern Bellinzona, Bellinzona, Switzerland; Sanofi-Aventis, Alnwick, United Kingdom; Sanofi-Aventis, Chilly-Mazarin, France
| |
Collapse
|
44
|
Rinaldi S, Consales G, Gallerani E, Ortolani O, De Gaudio AR. A-line autoregression index monitoring to titrate inhalational anaesthesia: effects on sevoflurane consumption, emergence time and memory. Acta Anaesthesiol Scand 2005; 49:692-7. [PMID: 15836686 DOI: 10.1111/j.1399-6576.2005.00658.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND A-line autoregression index (AAI) is a parameter derived from auditory evoked potentials proposed as depth of anaesthesia monitor. We evaluated the effects of AAI guidance on sevoflurane consumption, emergence time, explicit and implicit memory. METHODS One hundred patients submitted to major abdominal surgery were randomized into two groups. In group A (n = 50), sevoflurane was titrated according to AAI (target = 20 +/- 5), in group B (n = 50) according to clinical signs. Anaesthesia was induced with fentanyl, propofol, atracurium and maintained with sevoflurane. The mean value of sevoflurane consumption (g/min) and emergence time has been assessed in both groups. After emergence, A test of explicit memory was administered. We assessed implicit memory using a category generation test. RESULTS In group A, mean sevoflurane consumption was significantly (P = 0.0001) reduced by 20.4% and mean emergence time was significantly (P = 0.00012) shorter by 2 min with respect to group B. No patients experienced explicit memory while the difference between the two groups in implicit memory results was not significant (P = 0107). CONCLUSIONS AAI titration of anaesthesia allows a significant reduction in sevoflurane consumption and emergence time without significant effects on the incidence of explicit and implicit memory. Nevertheless the relationship between AAI and memory requires studies in larger groups of patients.
Collapse
Affiliation(s)
- S Rinaldi
- Department of Critical Care, Section of Anaesthesiology and Intensive Care, University of Florence, Viale Morgagni 85, 50125 Florence, Italy
| | | | | | | | | |
Collapse
|
45
|
Abstract
Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.
Collapse
Affiliation(s)
- G Biasco
- Institute of Hematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, S. Orsola-Malpighi Hospital, Italy.
| | | |
Collapse
|
46
|
Viaggi S, Gallerani E, Molina F, Nuesse M, Fronza G, Ottaggio L, Campomenosi P, Abbondandolo A, Menichini P. Partial characterization of SUVi, a new mammalian gene induced by UV-C and expressed during the S phase of the cell cycle. Environ Mol Mutagen 2001; 37:76-84. [PMID: 11170244 DOI: 10.1002/1098-2280(2001)37:1<76::aid-em1008>3.0.co;2-v] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
By using a lacZ-based gene-trap approach, we identified a mammalian gene induced by UV-C in a Chinese hamster ovary cell clone (Menichini P et al. [1997]: Nucleic Acids Res 25:4803-4807). The activity of the encoded protein fused to a bacterial beta-galactosidase was followed through the hydrolysis of different beta-galactosidase substrates. In this study we describe how the expression of this gene is modulated during the cell cycle and in response to UV-irradiation. We show that the beta-galactosidase activity was virtually undetectable in quiescent cells (G[0]), started to increase when cells progressed in G(1), and reached a maximum in mid-S phase, indicating a possible role of the endogenous protein during DNA synthesis. Following UV-irradiation, besides a delay of the progression through the S phase, a twofold increase of the reporter protein activity in all phases of the cell cycle was observed. The partial sequence analysis showed that this gene, here named SUVi (for S phase UV-inducible), contains a domain that is highly conserved among different helicases. Together, these data suggest that the SUVi gene could be involved in DNA synthesis, a process that takes place both in the S phase and in the processing of UV-induced damage.
Collapse
Affiliation(s)
- S Viaggi
- Department of Oncology, Biology, and Genetics, University of Genoa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Tamberi S, Gallerani E, Bazzocchi R, Zompatori M, Martinelli G, Schiavina M, Di Marco M, Brandi G, Biasco G. Carboplatin (CBDCA) and paclitaxel (TAX) as induction chemotherapy in stage IIIA–IIIB in non small cell lung cancer (NSCLC). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81472-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Menichini P, Viaggi S, Gallerani E, Fronza G, Ottaggio L, Comes A, Ellwart JW, Abbondandolo A. A gene trap approach to isolate mammalian genes involved in the cellular response to genotoxic stress. Nucleic Acids Res 1997; 25:4803-7. [PMID: 9365260 PMCID: PMC147125 DOI: 10.1093/nar/25.23.4803] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Treatment of cells with DNA damaging agents leads to induction of a variety of genes involved in different cellular processes. We have applied a lacZ-based gene trap strategy to search for new mammalian genes induced by genotoxic stress. A population of 32 x 10(3) neo r clones stably transfected with a gene trap vector was obtained, stained with fluorescein di-beta-d-galactopyranoside and analyzed by flow activated cell sorting and replica plating. This strategy allowed isolation of 30 neo r 'putative inducible' cell lines expressing lacZ only after a DNA damaging treatment. For three clones the site of integration and the degree of inducibility after UV treatment were determined by Southern blot and beta-galactosidase measurement respectively. One cell line (clone VI) showed a single integration site and a reproducible 3-fold induction of beta-galactosidase activity following UV irradiation. Fused transcripts were isolated from induced cells and a portion of the trapped gene was amplified by rapid amplification of cDNA ends. Sequence analysis and comparison with available gene and protein databanks revealed that the gene was novel.
Collapse
Affiliation(s)
- P Menichini
- CSTA-Laboratory of Mutagenesis, National Institute for Research on Cancer (IST), Largo Rosanna Benzi, 10, Genoa, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Bolognesi C, Gallerani E, Bonatti S, De Ferrari M, Fontana V, Valerio F, Merlo F, Abbondandolo A. Sister chromatid exchange induction in peripheral blood lymphocytes of traffic police workers. Mutat Res 1997; 394:37-44. [PMID: 9434841 DOI: 10.1016/s1383-5718(97)00121-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Traffic police workers, as a population exposed to urban atmosphere, were compared with a control population exposed to indoor air pollution levels. Sister chromatid exchanges (SCEs) as a biomarker of effect were measured in peripheral blood lymphocytes of 54 exposed subjects and 35 controls, and environmental concentration of polynuclear aromatic hydrocarbon (PAH) tracer compounds was detected by personal air samplers. The mean exposure level to benzo[a]pyrene in our group of traffic policemen (3.4 mg/m3) was in the range that has been estimated in urban areas in Europe during the last 10 years. No difference in SCE levels was found between exposed workers (7.36, SD 1.35) and controls (7.47, SD 1.28). No correlation was observed between SCE/cell and airborne PAH concentration in the traffic worker population. A positive regression of SCE on exposure estimate was found only in the non-smoking group of police workers. Our findings suggest that exposure to urban air pollution does not induce relevant cytogenetic effects.
Collapse
Affiliation(s)
- C Bolognesi
- Environmental Oncology Department, Istituto Nazionale per la Ricerca sup Cancro, Genoa, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Miele M, Donato F, Hall AJ, Whittle H, Chapot B, Bonatti S, De Ferrari M, Artuso M, Gallerani E, Abbondandolo A, Montesano R, Wild CP. Aflatoxin exposure and cytogenetic alterations in individuals from the Gambia, West Africa. Mutat Res 1996; 349:209-17. [PMID: 8600352 DOI: 10.1016/0027-5107(95)00180-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Aflatoxin-albumin adducts in peripheral blood provide a measure of exposure to aflatoxin over the previous 2-3 months. In the present study, the levels of these adducts were determined in a group of individuals from The Gambia, West Africa and were compared in a cross-sectional study to the levels of various cytogenetic alterations (chromosomal aberrations, micronuclei, sister chromatid exchanges) in the same individuals to test whether an increase in genetic damage is associated with an increased exposure in this population. Of 35 subjects tested for aflatoxin-albumin adducts, all but 3 were positive. There were no correlations between the adduct level and the number of cytogenetic abnormalities at the individual level. A comparison of the cytogenetic alterations was made between Gambian individuals and a group of 22 healthy people from Italy where aflatoxin exposure is expected to be low. The levels of structural chromosomal aberrations, sister chromatid exchanges and micronuclei were all higher in the former group. Overall, these data are indicative of a higher exposure to genotoxins in Gambian subjects, one of which are aflatoxins, but suggest that more specific genetic markers of aflatoxin exposure are required to further examine the link between aflatoxin exposure and genetic alterations.
Collapse
Affiliation(s)
- M Miele
- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|